AAI101, a Novel β-Lactamase Inhibitor: Microbiological and Enzymatic Profiling

BACKGROUND: AAI101 is a novel β-lactamase inhibitor (BLI), active against ESBLs and other β-lactamases. AAI101 combined with cefepime (FEP) is in Phase 2 clinical trials. The objective of this study was to determine differences between AAI101 and tazobactam in their inhibition of selected β-lactamas...

Descripción completa

Detalles Bibliográficos
Autores principales: Papp-Wallace, Krisztina M, Bethel, Christopher R, Barnes, Melissa D, Rutter, Joseph D, Taracila, Magdalena A, Bajaksouzian, Saralee, Jacobs, Michael R, Bonomo, Robert A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631055/
http://dx.doi.org/10.1093/ofid/ofx163.924

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631055/
http://dx.doi.org/10.1093/ofid/ofx163.924

Ejemplares similares